OncoSec Medical Obtains Allowance of Key Patent Application for Intratumoral Delivery of Plasmid IL-15
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announces that the United States Patent and Trademark Office (USPTO) has allowed claims covering a method of treating cancerous tumors with plasmid-encoded IL-15 and electroporation therapy to the tumor having a field strength of at least 700 V/cm. This announcement enhances OncoSec’s IP portfolio and provides significant support to the ongoing expansion of its immuno-oncology pipeline.
"This patent allowance by the USPTO demonstrates our strong overall commitment to protecting the innovation and commercial opportunity of our entire intratumoral immunotherapy product portfolio," said Punit Dhillon, president and chief executive officer, OncoSec Medical. “IL-15 is regarded as a promising immunotherapeutic agent, with several other companies evaluating IL-15 in clinical trials, as well as the National Institutes of Health. Our delivery approach of electroporation with plasmid IL-12 has demonstrated an excellent safety profile without unwanted toxicities. This patent allowance provides further evidence of OncoSec’s role as a leader in the development of intratumoral immunotherapies.”
IL-15 is a member of the family of IL-2 cytokines. This family of cytokines activates signaling pathways leading to cellular activation, proliferation and survival. Specifically, IL-15 exhibits broad activity and induces differentiation and proliferation of immune cells, such as Natural Killer (NK) cells, T cells and B cells. Furthermore, IL-15 reverses tolerance to tumor-associated antigens. Thus, IL-15 potentiates the immune system, which is important in the immune system’s ability to recognize and kill the cancer.
The allowed patent application joins a family of two issued U.S. patents: U.S. 8,026,223, which claims a method of treating cancerous tumors with plasmid-encoded IL-12 and electroporation therapy to the tumor; and U.S. 8,802,643, which claims a method of treating cancerous tumors with plasmid-encoded B7-1, a peripheral membrane protein found on antigen-presenting cells (APCs), and electroporation therapy to the tumor, both of which have a field strength of at least 700 V/cm. This patent family was exclusively licensed by OncoSec from the University of South Florida.
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Source: OncoSec Medical Inc.